208 related articles for article (PubMed ID: 34804001)
1. Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report.
Tang X; Zhou W; Huang D; Chen L; Zhang G
Front Immunol; 2021; 12():688682. PubMed ID: 34804001
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
Makowska A; Lelabi N; Nothbaum C; Shen L; Busson P; Tran TTB; Eble M; Kontny U
Cells; 2021 Sep; 10(9):. PubMed ID: 34572108
[TBL] [Abstract][Full Text] [Related]
3. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
5. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Adkins DR; Haddad RI
Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.
Johnson D; Ma BBY
Oral Oncol; 2021 Feb; 113():105127. PubMed ID: 33454551
[TBL] [Abstract][Full Text] [Related]
8. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
Shi M; Sun D; Ma X; Liu J; Zhang Y; Liu T; Chen X; Mo S; Zhao Y; Zhang L
Hum Vaccin Immunother; 2023 Dec; 19(3):2294579. PubMed ID: 38111107
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.
Fei Z; Deng Z; Zhou L; Li K; Xia X; Xie R
Oncol Res; 2019 Jul; 27(7):801-807. PubMed ID: 30982497
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
11. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
[TBL] [Abstract][Full Text] [Related]
12. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.
Feng C; Zhang Y; Huang J; Zheng Q; Yang Y; Xu B
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):239-244. PubMed ID: 32205739
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
Yang Y; Zhou T; Chen X; Li J; Pan J; He X; Lin L; Shi YR; Feng W; Xiong J; Yang K; Yu Q; Zhang Q; Hu D; Sun Y; Hu G; Li P; Shen L; Lin Q; Zhang B; Qu X; Zou J; Zhang L; Fang W; Zhao Y
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933967
[TBL] [Abstract][Full Text] [Related]
16. A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
Li L; Chen L; Fan M; Tian Y; Ai H; Yan L; Li F; Lan M; Lai X; Huang Y; Xu P; Feng M; Lang J
Oral Oncol; 2024 Mar; 150():106695. PubMed ID: 38262250
[TBL] [Abstract][Full Text] [Related]
17. Distribution pattern and prognosis of metastatic lymph nodes in cervical posterior to level V in nasopharyngeal carcinoma patients.
Jiang C; Gao H; Zhang L; Li H; Zhang T; Ma J; Liu B
BMC Cancer; 2020 Jul; 20(1):667. PubMed ID: 32680466
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
Front Immunol; 2021; 12():705096. PubMed ID: 34434192
[TBL] [Abstract][Full Text] [Related]
20. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
Chan OS; Kowanetz M; Ng WT; Koeppen H; Chan LK; Yeung RM; Wu H; Amler L; Mancao C
Oral Oncol; 2017 Apr; 67():52-60. PubMed ID: 28351581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]